Portfolio goal: growth. This is a high beta, unapologetic growth portfolio with some safeguards and some boring investments. The goal remains unchanged.

The great potential of a drug or remedy that may make it a significant seller and revenue driver for years to come is one thing. But the partners and interested parties early on and along the way suggests a depth that a long term stakeholder should pay attention to.